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Summary. The primary goal of prophylaxis in patients
with severe haemophilia is to convert the phenotype from
severe to moderate and to prevent the development of
chronic arthropathy. Prior studies have demonstrated
that prophylaxis decreases episodes of joint bleeds and
chronic arthropathy. Effectiveness depends on prescrip-
tion of prophylaxis and adherence to the prescribed
regimen. The aim of this study was to determine if
prescription of prophylaxis for children with haemo-
philia and perceptions of adherence to prophylaxis have
changed since publication of the Joint Outcome Study
(JOS). A questionnaire was sent, in electronic and written
formats, to health professionals who provide care to
children with haemophilia at US haemophilia treatment
centres (HTCs). The response rate was 56 of 128 (44%)
of the targeted HTCs. There were a few missing data and
denominators are provided. All responses agreed with the
results of the JOS and 30/55 (55%) reported the JOS
increased their prescription of prophylaxis. Nineteen of
56 (34%) physicians or HTC staff reported that they had
not prescribed prophylaxis within the last year due to
concerns about adherence, and 19/56 (34%) reported
they had stopped prophylaxis due to concerns about
adherence within the last year. Predicted adherence
decreased with increasing age. Prescription of prophy-
laxis appears to be increasing since publication of the
JOS. Strategies to improve adherence may increase the
likelihood of physician prescription of prophylaxis and
make prophylaxis easier to implement for individual
patients, thereby improving the clinical outcome of
children and adults with haemophilia.
Keywords: haemarthrosis, haemophilia, prophylactic treat-
ment, treatment adherence
Introduction
Patients with severe haemophilia are at risk for frequent
joint haemarthrosis. Chronic arthropathy develops after
repeated joint haemarthrosis and is associated with
muscle wasting, morning stiffness, limited movement,
chronic pain, decreased functional status and poor
quality of life; chronic arthropathy is a devastating and
costly complication of haemophilia [1]. Prophylactic
factor replacement (prophylaxis) is given 1–4 times per
week to prevent bleeding; many treaters attempt to
maintain factor levels above 1% to ensure effective
bleed prevention. The primary goal of prophylaxis in
patients with severe haemophilia is to convert the
bleeding phenotype from severe to moderate and to
prevent the development of chronic arthropathy [2,3].
Prior studies, including the randomized, controlled,
Joint Outcomes Study (JOS) and the Italian randomized
clinical trial of prophylaxis in children with haemo-
philia (the ESPRIT study) have demonstrated prophy-
laxis decreases joint bleeds and chronic arthropathy
[4–9]. However, effectiveness of prophylaxis depends
on treaters prescribing prophylaxis and patients adher-
ing to the prescribed regimen. Prior to the publication of
the JOS, we found that 86% of physicians reported that
they prescribe prophylaxis on a routine basis. At the
same time, only 54% of physicians reported that
76–100% of patients administer at least 80% of the
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recommended infusions [10]. The aim of this study was
to determine if prescription of prophylaxis for children
with haemophilia and perceptions of adherence to
prophylaxis have changed since publication of the JOS.
Materials and methods
We developed a questionnaire, in electronic and written
formats, based on literature review and expert opinion.
The questionnaire was designed by two paediatric (SC
and CT) and one adult (CL) haemophilia treatment
centre (HTC) physicians and two HTC nurses (JM and
SZ). The goal was to determine current prophylaxis
practice and perceptions of adherence to prophylaxis.
Excellent adherence was defined as giving ‡80% of
prescribed infusions; this definition is commonly used in
clinical trials to define adherence [11–14]. Prophylaxis
was defined as long-term continuous (at least 46 weeks
per year) treatment with factor. Primary prophylaxis
was defined as initiated prior to the development of a
target joint and secondary prophylaxis was defined as
initiated after development of a target joint. The
questionnaire contained 21 multiple choice questions,
six Likert-scale questions, and one open-ended question
(see Data S1). The questionnaire took on average
20 min to complete. The survey was administered to
health professionals at HTCs. The Centers for Disease
Control and Prevention (CDC) HTC staff database
(available at https://www2a.cdc.gov/ncbddd/htcweb)
[15] was used to identify physicians, physician extend-
ers, and nurses who care for children with haemophilia.
Respondents were expected to self-report based on
practice at their HTC. The questionnaire was sent in
hardcopy by mail and in electronic format with a link to
the questionnaire in Survey Monkey. If multiple ques-
tionnaires were completed at a site, only the first
questionnaire received was included.
Statistical analysis
Descriptive statistics were performed. Pearson chi-
squared tests and Wilcoxon tests were done to compare
responses between the current respondents and respon-
dents of the prior survey published by Thornburg [10]
and to compare responses between those who reported
that their prescription of prophylaxis has increased
since publication of the JOS and those who reported
that their prescription stayed the same.
Results
Fifty-six responses were received from health profes-
sionals at HTCs who provide care to children with
haemophilia. The response rate was 56 of 128 (44%) of
the targeted HTCs. There were occasional missing data
and denominators are provided for each response.
Demographics of respondents
Characteristics of the respondents are shown in Table 1.
Prescription of prophylaxis
Forty-eight of 55 (87%) respondents reported that they
prescribe prophylaxis on a regular basis compared with
86% (51/59) in the prior study (P = 0.91). Responses
did not vary by role at HTC, years of experience, or size
of program. Responses did vary based on or whether or
not the respondent cares for both adult and paediatric
patients with haemophilia. A larger portion of respon-
dents who indicated they do not prescribe prophylaxis
on a routine basis were at HTCs that primarily take care
of children compared with the proportion who indi-
cated that they do prescribe prophylaxis on a routine
basis (P = 0.04). Health professionals were asked to
report their primary reason for prescription of prophy-
laxis for the following age ranges: 12–23 months,
2–5 years, 6–12 years and 13–18 years. The frequencies
of primary and secondary prophylaxis by age were the
following: age 12–23 months (primary 45/54, 83%;
secondary 9/54, 17%); age 2–5 years (primary 40/54,
74%; secondary 14/54, 26%); 6–12 years (primary 24/
53, 45%; secondary 29/53, 55%); and 13–18 years
(primary 16/65, 29%; secondary 40/56, 71%). The
frequency of prophylaxis prescription by age and type
of prophylaxis (primary vs. secondary) is shown in
Fig. 1 (panel a and b). Respondents were asked about
factors which motivate prescription of prophylaxis,
Table 1. Characteristics of haemophilia care providers completing survey.
Survey responses, N (%)
Role at haemophilia treatment centre
Physician 36/56 (64)
Nurse practitioner 6/56 (11)
Nurse 14/56 (25)
Experience (years)
0–5 3/56 (5)
6–10 6/56 (11)
11–20 27/56 (48)
21–40 19/56 (34)
>40 1/56 (2)
Region
I 5/56 (9)
II 5/56 (9)
III 5/56 (9)
IV North 3/56 (5)
IV South 4/56 (7)
V West 5/56 (9)
V East 10/56 (18)
VI 3/56 (5)
VII 3/56 (5)
VIII 4/56 (7)
IX 7/56 (12)
X 2/56 (4)
Children treated at haemophilia treatment centre (N)
1–10 2/56 (4)
11–50 11/56 (20)
51–100 22/56 (39)
>100 21/56 (38)
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factors which impact the prescription of prophylaxis,
and factors which may limit the prescription of
prophylaxis. These data are presented in Table 2.
Impact of the joint outcomes study on the
prescription of prophylaxis
Hundred per cent of respondents strongly agreed or
agreed with the conclusions of the JOS (Table 3). Fifty-
five per cent (30/55) reported the JOS increased
prescription of prophylaxis, while 45% (25/55)
reported that the JOS did not impact their prescription
of prophylaxis. Increase in prescription of prophylaxis
since the JOS was more frequently reported by nurse
practitioners and nurses compared with physicians
(P = 0.03), providers with fewer years of experience
(P = 0.01), and those with a smaller number of children
followed at the HTC (P = 0.04). Of the 30 respondents
who reported that the JOS increased the prescription of
prophylaxis, 21/30 (70%) reported they are more
convinced that prophylaxis improves joint outcomes;
25/30 (83.3%) reported they are able to convince more
patients that prophylaxis is worthwhile; 14/30 (46.7%)
report the results of the study improve adherence with
prophylaxis; and 18/30 (60%) report that insurance
companies are more likely to cover prophylaxis. Of the
25 who reported the JOS did not increase their
prescription of prophylaxis, 24/25 (96%) reported they
already prescribe prophylaxis for the majority of their
patients and 1/25 (4%) reported there are too many
barriers to prophylaxis.
Among all of the respondents, 22/55 (40%) reported
that the Canadian study of tailored prophylaxis [16] has
increased their prescription of prophylaxis and 10/55
(18.2%) reported that the German study of early
prophylaxis to prevent inhibitor formation [17] has
increased their prescription of prophylaxis.
Adherence and outcomes assessment
The most common measures to assess adherence
included frequency of joint bleeds (51/56; 91%), joint
examination (41/56; 73%), hand written logs (42/56;
75%) and pharmacy records (38/56; 68%). Only one
Fig. 1. Haemophilia care provided reported prescription of prophylaxis by age group. Survey respondents were asked for what percentage of their patients
they prescribe primary prophylaxis (panel a) and secondary prophylaxis (panel b). Response categories included 0–25%, 26–50%, 51–75% and 76–100%.
Respondents were asked to provide a response for the following age groups: 12–23 months (for primary prophylaxis only), 2–5 years, 6–12 years and
13–18 years. Percentage of respondents for each category is shown on the y-axis.
Table 2. Factors which motivate physician
prescription of prophylaxis.Always/Almost
Always, N (%)
Often,
N (%)
Sometimes,
N (%)
Never,
N (%)
Factors which motivate prescription
Family history of haemarthrosis 4/56 (7) 8/56 (14) 24/56 (43) 20/56 (36)
Personal history of haemarthrosis 34/56 (61) 18/56 (7) 4/56 (7) 0
Personal history of soft tissue bleeds 12/55 (22) 18/55 (33) 20/55 (36) 5/55 (9)
Family request 9/56 (16) 20/56 (36) 23/56 (41) 4/56 (7)
Factors which impact prescription of prophylaxis
Family history of inhibitor 11/56 (20) 11/56 (20) 20/56 (36) 14/56 (25)
Type of genetic mutation 4/56 (7) 11/56 (20) 20/56 (36) 21/56 (38)
Factors which decrease prescription of prophylaxis
Financial concerns 1/56 (2) 5/56 (9) 34/56 (61) 16/56 (29)
Lack of venous access 6/56 (22) 9/56 (16) 31/56 (55) 10/56 (18)
Concerns about adherence 2/56 (4) 7/56 (13) 40/56 (71) 7/56 (13)
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individual indicated that they utilized a haemophilia-
specific adherence measure.
Overall, 20/48 (42%) of respondents reported 76–
100% of patients administer ‡80% of recommended
infusions compared with 32/59 (54%) of respondents in
the prior study (P = 0.55). Responses indicating 76–
100% of patients administer at least 80% of prescribed
prophylaxis did not vary by role at HTC, years of
experience, size of program or whether or not respon-
dent also cares for adult patients with haemophilia.
Reported adherence decreased with increasing age
group (Fig. 2). Nineteen of 56 (34%) respondents
reported they had not prescribed prophylaxis to at least
one patient within the last year due to concerns about
their patient not being adherent to the prophylactic
treatment ordered and 19/56 (34%) reported they had
stopped prophylaxis for at least one patient due to
concerns about the patient not being adherent with their
treatment within the last year.
Respondents were queried if they would prescribe
prophylaxis based on four clinical scenarios. All four
scenarios concerned a two-year-old boy with severe
haemophilia A with a history of haematomas, two
episodes of oral bleeding and one joint bleed. In
scenario 1, the child lives with his mother (a home-
maker), father (university professor) and sister, and the
child does not have difficulty with venous access. In
scenario 2, the home situation is the same, but venous
access has been difficult for on-demand infusions. In
scenario 3, the child lives with his mother (employed in
several part-time jobs) and three siblings, and the child
does not have difficulty with venous access. In scenario
4, the child lives with his mother (employed in several
part-time jobs) and three siblings, and venous access has
been difficult for on-demand infusions. The percentage
of respondents who would prescribe prophylaxis for
similar patients was 47/55 (85%), 44/55 (80%), 50/55
(91%), and 44/55 (80%) respectively. For scenarios 2
and 4, involving difficult venous access, respondents
indicated that they would place a port and/or involve
homecare to facilitate infusions or consider starting
once-weekly regimen. For scenarios 3 and 4 one
respondent reported he/she would prescribe prophylaxis
‘because unexpected bleeds would be quite difficult for
this family and may even lead to delays in treatment,’
and another indicated ‘I don’t think the social situation
should define prophylaxis in most cases. In this setting,
bleeding would be a disaster for her jobs.’
Discussion
In our study of health professionals who prescribe
prophylaxis for children with haemophilia, although the
reported rate of prophylaxis was the same as with our
prior study, 55% indicated that their prescription of
prophylaxis increased since publication of the JOS. This
is consistent with data from the CDC Universal Data
Collection (UDC) program which shows that as of
2010, 53% of patients with severe haemophilia are
prescribed prophylaxis compared with 37% and 48%
in 2002 and 2006 respectively [18]. Based on the survey
responses, it appears the JOS has been influential on
health care providers who have not previously pre-
scribed prophylaxis for the majority of their patients,
particularly nurses and nurse practitioners as well as
those with fewer years of experience and those at
smaller HTCs. In addition, the clinicians report that the
JOS provides important information which can be used
Table 3. Changes in prescription of prophylaxis since publication of the
Joint Outcomes Study.
N (%)
Reasons JOS increased prescription of prophylaxis (N = 30)
More convinced that prophylaxis improves joint
outcomes
21/30 (70)
Able to convince more patients that prophylaxis is
worthwhile
25/30 (83.3)
Results of study improve adherence with prophylaxis 14/30 (46.7)
Insurance companies are more likely to cover
prophylaxis
18/30 (60)
Reasons JOS did not increase prescription of prophylaxis (N = 25)
Not aware of the results of the JOS 0
Already prescribe prophylaxis to the vast majority
of patients
24/25 (96)
Results not convincing 0
Too many barriers to prophylaxis 1/25 (4)
Other studies which impact prescription of prophylaxis (N = 55)
Canadian study of tailored prophylaxis [16] 22/55 (40)
German study of early prophylaxis regimen to
reduce inhibitors [17]
10/55 (18.2)
Fig. 2. Haemophilia care provider reported patient adherence to prophy-
laxis by age group. Survey respondents were asked what per cent of their
patients administer ‡80% of prescribed prophylaxis. Response categories
included 0–25%, 26–50%, 51–75% and 76–100%. Respondents were
asked to provide a response for the following age groups: 12–23 months,
2–5 years, 6–12 years and 13–18 years. Percentage of respondents for each
category is shown on the y-axis.
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to educate patients about prophylaxis and can be
provided to insurers.
The survey for the current study had more in depth
questions regarding prescription of prophylaxis by
querying practice based on age of patient and type of
prophylaxis. Thirty per cent of respondents reported
they prescribe primary prophylaxis to >75% of eligible
patients ages 12–23 months compared with 50% of
respondents who reported prescribing prophylaxis for
>75% of eligible patients at older ages. Respondents
more often reported prescribing secondary prophylaxis
to eligible patients than prescribing primary prophy-
laxis. These data likely reflect the fact that the primary
reason for prophylaxis was a history of joint haemarth-
rosis. Based on the UDC study the rate of prophylaxis
for children ages 2–5 years increased from 36 to 38%
between the reporting periods of 2006 to 2010 [18].
This trend may continue due to the growing evidence
from the JOS [8] and ESPRIT [9] studies of the benefits
of prophylaxis starting at a young age. Other motivat-
ing factors for prophylaxis included history of soft
tissue bleeds, family request and family history of
inhibitor. Of interest, 20% of respondents indicated
that they always or almost always consider family
history of inhibitor as a reason for primary prophylaxis;
75% consider it at least sometimes. Sixty-two per cent
indicated they at least sometimes consider the type of
genetic mutation as a reason for primary prophylaxis,
indicating that clinicians are starting to consider risk-
based approaches to prophylaxis prescription. In addi-
tion, 40% reported the Canadian study of tailored
prophylaxis [16] has increased their prescription of
prophylaxis and 18% reported the German study of
early prophylaxis to prevent inhibitor formation [17]
has increased their prescription of prophylaxis reflecting
a tailored approach to prophylaxis. Other factors which
contribute to decisions to start prophylaxis include
venous access and impact of unpredictable bleeds on the
child and family. Central venous catheters, nursing
services and graduated prophylaxis strategy can help to
facilitate prophylaxis.
Barriers
As the reported rate of prescription of prophylaxis
remains high and may be increasing, prescription of
prophylaxis is not universal. Only 2% of respondents
indicated that financial concerns are always or almost
always a limiting factor. On the other hand, only 29%
per cent of respondents said that financial concerns were
never an issue. Lack of access was also reported as a
substantial limitation.
Adherence
Adherence is also a barrier to implementation of
prophylaxis. Clinicians primarily use joint bleeds/exam-
ination, hand written logs and pharmacy records to
assess adherence. Although there is a newly validated
measure of adherence with prophylaxis (VERITAS-Pro)
[19] this measure has not been widely adopted in clinical
practice. In response to a survey of Canadian haematol-
ogists and nurses, 12.5% of physicians and 17.6% of
nurses indicated that they do not assess adherence [20].
Based on the adherence measures, only 42% of respon-
dents reported that >75% of their patients have excellent
adherence (‡80% of prescribed doses) with prophylaxis.
Strikingly, 70% of respondents reported that >75% of
their patients aged 1–5 years have excellent adherence
compared with 22% of respondents who reported that
>75% of their adolescent patients have excellent adher-
ence. These data are similar to those of Chan et al.where
50% of physicians in Canada indicated children were
80–100% adherent and 19% indicated adolescents were
80–100% adherent [20]. Adolescence and transition to
adulthood may be a significant barrier to adherence with
prophylaxis and clinicians have identified poor adher-
ence by adolescents as a reason not to prescribe
prophylaxis to that group. Up to two-thirds of young
adults will experiment with stopping or reducing doses
of prophylaxis when they take responsibility for self-
infusion [21], because they do not think they need
prophylaxis [22].
Perceptions of adherence influence prescription of
prophylaxis [10]. Richards et al. conducted a survey of
21 haemophilia doctors, throughout Europe, to study
practice and opinions regarding prophylaxis in 5000
patients aged 16–24 and >50 years [23]. Eighteen of 19
doctors indicated that they would consider modifying
prophylaxis in a median of 70% of adolescent/young
adult patients, typically ages 16–20 years. Recom-
mended changes included reducing the frequency of
dosing, reducing the dose per infusion and changing to
on-demand with option to restart in the future. This is
in comparison to no doctors recommending similar
changes in children <16 years. One of the top three
reasons for these recommendations was concern about
poor adherence. Similarly, Walsh and Valentino recently
published a survey of US HTCs regarding factor VIII
prophylaxis for adult patients with severe haemophilia
A [24]. In this survey, the most important reason for not
recommending prophylaxis to adult patients was con-
cern that adults would not adhere to prophylaxis [24].
Clinicians responding to our questionnaire also indi-
cated they may not prescribe prophylaxis or may stop
prophylaxis due to concerns that their patient is not
adhering to the regimen.
It is critical to address the issue of non-adherence,
particularly in adolescents, as this may lead to improved
outcomes. There is not a gold standard for improving
adherence for medication. The need for strategies to
improve medication and treatment adherence is not
unique to haemophilia. Improving adherence requires a
multi-faceted, tailored approach [25,26]. The exact
572 C. D. THORNBURG et al.
Haemophilia (2012), 18, 568–574  2012 Blackwell Publishing Ltd
approach depends on specific patient-related barriers to
adherence. For example, if knowledge is a key barrier,
strategies to improve education can be developed.
Education topics should include the benefits and risks
of prophylaxis including data from research studies as
well as education on all of the steps required for
successful administration. Education should be tailored
to the health literacy of the audience and should include
clear and concise information in spoken, electronic and
written media. Families should be asked to explain what
they know about the recommendations and demon-
strate required medication administration skills. Educa-
tion should continue throughout the course of
prophylaxis and directed toward to the child/adolescent
when appropriate. If families have difficulty remember-
ing to order factor or to administer factor, more
frequent follow-ups at the HTCs or through phone
calls may be useful. Providing feedback on response can
reinforce the rationale for prophylaxis; HTCs may work
with families to identify the best methods by which to
integrate prophylaxis into daily life. If venous access is a
barrier, HTCs may elect to start prophylaxis once
weekly while parents learn to infuse their children. In
fact, in a recent survey by Ragni et al., greater than
30% of US HTCs indicate they initiate prophylaxis with
a once weekly schedule [27]. If peripheral venous
infusion is not successful, placement of a central venous
catheter may facilitate prophylaxis. In the same study,
30% indicated 100% of patients require central venous
catheters for prophylaxis.
The primary limitation of this study was that the data
were self-reported rather than abstracted from individ-
ual site chart review. However, years and depth of
experience amongst respondents supports the validity of
the study. The study is also limited as we did not design
the study to capture patient-reported reasons for
decreased adherence.
Conclusion
Prophylaxis is an efficacious method for primary and
secondary prevention of joint haemarthrosis. Ongoing
research studies will lead to risk-based, tailored pro-
phylaxis strategies. A limiting factor is adherence with
prophylaxis. Strategies to improve adherence may
increase the likelihood of physician prescription of
prophylaxis and make prophylaxis easier to implement
for individual patients, thereby improving the clinical
outcome of children and adults with haemophilia.
Multi-faceted and tailored approaches to improve
adherence should be developed and tested.
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